!xt! - Lombart Instrument › store › pub › media › ...1881 1.8 1.6 1.4 1.2 0.8 0.6 0.4 0.2...

1
Clinical Effectiveness of Lid Debridement with BlephEx Treatment Daniel Mulder, Kirs/ Kyser, Bonnie Rosenberg, Charles Connor, Christopher Choat, Srihari Narayanan University of the Incarnate Word, Rosenberg School of Optometry, San Antonio, Texas ABSTRACT Purpose: Eyelid disease is a common cause of evaporaBve dry eye. Lid scrubs and warm compresses done consistently will address this problem but poor compliance makes an office based procedure desireable. Korb found the debridementIscaling of the lower lid margin provides staBsBcally significant symptom relief and improvement in the meibomian gland (MG)funcBon. The Bleph Ex provides a method of accomplishing lid debridement without using a surgical instrument. This study compares signs and symptoms before and aPer BlephEx treatment. Methods: Twenty subjects all with MG dysfuncBon were examined at baseline using a biomicroscope using the Efron scale for grading. Subjects also had a TBUT and OSDI performed. The subjects were then treated with the BlephEx according to manufacturer’s direcBons. 4 weeks later all tesBng was repeated. Data was analyzed by a tItest with post hoc test for significance. Results: Subjects TBUT improved from 3.31+/I1.3 to 5.47+/I4.3 p=0.05. BlephariBs on the Efron scale improved from 1.24+/I0.69 to 0.575+/I0.54 p=0.01. MG dysfuncBon also dramaBcally improved from 1.65+/I0.5 to 0.76 +/I 0.59 p=0.01. Symptoms also improved based on the OSDI which went from 43.74+/I14.27 to 20.33+/I14.35 p=0.01. Conclusions: This study suggests BlephEx is a viable alternaBve to lid scrubs and warm compresses. StaBsBcally significant improvement was observed in signs and symptoms of the subjects treated. Eyelid funcBons improved based on TBUT increase, reduced inflammaBon and enhanced MG funcBon. Subjects were 50% less symptomaBc aPer treatment. BlephEx appears to be a reasonable clinical approach for use nonIcompliant MG dysfuncBon paBents. BACKGROUND Rynerson introduced a new instrument in 2014 that aims at reducing the effects of blepharitis. The minimal invasiveness of the instrument makes it ideal for use by optometrists. This study examines changes in the signs and symptoms of the ocular surface before and after treatment with BlephEx. METHOD 20 subjects with MGD and dry eye symptoms participated in a prospective randomized study. All subjects underwent an initial baseline examination. All subjects then received the BlephEx treatment according to the manufacturer’s directions. Outcome measures obtained at baseline and 4 weeks post- treatment included: Biomicroscope examination using the Efron Grading Scale to grade MGD and Blepharitis severity Ocular Surface Disease Index (OSDI) Tear Break-Up Time Data was analyzed by a t-test with post hoc test for significance. EFRON GRADING SCALE Inferior lid margin OS; preItreatment blephariBs rated 2+ (moderate), 4 weeks postI treatment rated 0 (normal). RESULTS TBUTS significantly improved 4 weeks after treatment (p= 0.05) Blepharitis on the Efron Scale significantly improved 4 weeks after treatment (p=0.01) MG Dysfunction drastically improved 4 weeks after treatment (p=0.01) Symptoms also improved based on the OSDI 4 weeks after treatment (p=0.01) EYELID DEBRIDEMENT CONCLUSIONS BlephEx is a viable alternative to the conventional treatment (lid scrubs and warm compresses) for blepharitis Statistically significant improvement in signs & symptoms 4 weeks after treatment Increased TBUT, decreased inflammation, and increase in MG function after treatment Subjects were 50% less symptomatic after treatment Efron grading scale for BlephariBs and MGD Before APer

Transcript of !xt! - Lombart Instrument › store › pub › media › ...1881 1.8 1.6 1.4 1.2 0.8 0.6 0.4 0.2...

Page 1: !xt! - Lombart Instrument › store › pub › media › ...1881 1.8 1.6 1.4 1.2 0.8 0.6 0.4 0.2 Blepharitis Efron Grading Baseline .4 weeks MGD Efron Grading Scales for Contact Lens

Prin%ng: This,poster,is,48”,wide,by,36”,high.,

It’s,designed,to,be,printed,on,a,

large?format,printer.

Customizing,the,Content:

The,placeholders,in,this,poster,are,

formaFed,for,you.,Type,in,the,

placeholders,to,add,text,,or,click,

an,icon,to,add,a,table,,chart,,

SmartArt,graphic,,picture,or,

mul%media,file.

To,add,or,remove,bullet,points,

from,text,,just,click,the,Bullets,

buFon,on,the,Home,tab.

If,you,need,more,placeholders,for,

%tles,,content,or,body,text,,just,

make,a,copy,of,what,you,need,and,

drag,it,into,place.,PowerPoint’s,

Smart,Guides,will,help,you,align,it,

with,everything,else.

Want,to,use,your,own,pictures,

instead,of,ours?,No,problem!,Just,

right?click,a,picture,and,choose,

Change,Picture.,Maintain,the,

propor%on,of,pictures,as,you,resize,

by,dragging,a,corner.

!!

Clinical!Effectiveness!of!Lid!Debridement!with!BlephEx!Treatment!!Daniel'Mulder,'Kirs/'Kyser,'Bonnie'Rosenberg,'Charles'Connor,'Christopher'Choat,'Srihari'Narayanan'

University*of*the*Incarnate*Word,*Rosenberg*School*of*Optometry,*San*Antonio,*Texas**

ABSTRACT'Purpose:*Eyelid*disease*is*a*common*cause*of*evaporaBve*dry*eye.*Lid*scrubs*and*warm*compresses*done*consistently*will*address*this*problem*but*poor*compliance*makes*an*office*based*procedure*desireable.*Korb*found*the*debridementIscaling*of*the*lower*lid*margin*provides*staBsBcally*significant*symptom*relief*and*improvement*in*the*meibomian*gland*(MG)funcBon.*The*Bleph*Ex*provides*a*method*of*accomplishing*lid*debridement*without*using*a*surgical*instrument.*This*study*compares*signs*and*symptoms*before*and*aPer*BlephEx*treatment.**Methods:*Twenty*subjects*all*with*MG*dysfuncBon*were*examined*at*baseline*using*a*biomicroscope*using*the*Efron*scale*for*grading.*Subjects*also*had*a*TBUT*and*OSDI*performed.*The*subjects*were*then*treated*with*the*BlephEx*according*to*manufacturer’s*direcBons.*4*weeks*later*all*tesBng*was*repeated.*Data*was*analyzed*by*a*tItest*with*post*hoc*test*for*significance.**Results:*Subjects*TBUT*improved*from*3.31+/I1.3*to*5.47+/I4.3*p=0.05.*BlephariBs*on*the*Efron*scale*improved*from*1.24+/I0.69*to*0.575+/I0.54*p=0.01.*MG*dysfuncBon*also*dramaBcally*improved*from*1.65+/I0.5*to*0.76*+/I*0.59*p=0.01.*Symptoms*also*improved*based*on*the*OSDI*which*went*from*43.74+/I14.27*to*20.33+/I14.35*p=0.01.**Conclusions:*This*study*suggests*BlephEx*is*a*viable*alternaBve*to*lid*scrubs*and*warm*compresses.*StaBsBcally*significant*improvement*was*observed*in*signs*and*symptoms*of*the*subjects*treated.*Eyelid*funcBons*improved*based*on*TBUT*increase,*reduced*inflammaBon*and*enhanced*MG*funcBon.*Subjects*were*50%*less*symptomaBc*aPer*treatment.*BlephEx*appears*to*be*a*reasonable*clinical*approach*for*use*nonIcompliant*MG*dysfuncBon*paBents.***

BACKGROUND'Rynerson introduced a new instrument in 2014 that aims at reducing the effects of blepharitis. The minimal invasiveness of the instrument makes it ideal for use by optometrists. This study examines changes in the signs and symptoms of the ocular surface before and after treatment with BlephEx. *

METHOD'20 subjects with MGD and dry eye symptoms participated in a prospective randomized study. All subjects underwent an initial baseline examination. All subjects then received the BlephEx treatment according to the manufacturer’s directions. Outcome measures obtained at baseline and 4 weeks post-treatment included: Biomicroscope examination using the Efron Grading Scale to grade MGD and Blepharitis severity Ocular Surface Disease Index (OSDI) Tear Break-Up Time Data was analyzed by a t-test with post hoc test for significance. *

EFRON'GRADING'SCALE'

Inferior*lid*margin*OS;*preItreatment*blephariBs*rated*2+*(moderate),*4*weeks*postItreatment*rated*0*(normal).*

RESULTS'•  TBUTS significantly improved 4 weeks after

treatment (p= 0.05) •  Blepharitis on the Efron Scale significantly

improved 4 weeks after treatment (p=0.01) •  MG Dysfunction drastically improved 4 weeks after

treatment (p=0.01) •  Symptoms also improved based on the OSDI 4

weeks after treatment (p=0.01)

EYELID'DEBRIDEMENT'

CONCLUSIONS'•  BlephEx is a viable alternative to the conventional

treatment (lid scrubs and warm compresses) for blepharitis

•  Statistically significant improvement in signs & symptoms 4 weeks after treatment

•  Increased TBUT, decreased inflammation, and increase in MG function after treatment

•  Subjects were 50% less symptomatic after treatment

Efron*grading*scale*for*BlephariBs*and*MGD*

Before* APer*